Figure 7.

Network geometry for BCVA mean change from baseline. All populations of best-corrected visual acuity impaired and not impaired at 3-months follow-up [(A, B)] and 6-months follow-up [(C, D)]. BCVA, best-corrected visual acuity; CMT, central macular thickness. TA, intravitreal triamcinolone; IVB, intravitreal bevacizumab; LP, laser, macroscopic laser, grid laser and focal/grid laser; TA+LP, intrareal triamcinolone combined with laser; DEX, intravitreal dexamethasone; IVB+TA, intravitreal bevacizumab combined with triamcinolone; DEX+LP, intrareal dexamethasone combined with laser; IVR, intravitreal ranibizumab. Notes: Direct comparisons are represented by the black lines connecting the different interventions. Line width is proportional to the number of trials including every pair of interventions. The values of SUCRA are represented by the point size.